AptarGroup, Inc. 10-Q Summary: Quarter Ended June 30, 2009
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2009, for AptarGroup, Inc., a Delaware corporation. The company operates in the packaging components industry, developing and manufacturing consumer product dispensing systems. Operations are organized into three reporting segments: Beauty & Home, Closures, and Pharma. The filing reflects the impact of a global economic downturn and a strengthening U.S. dollar against the Euro.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2009 | Six Months Ended June 30, 2009 |
|---|---|---|
| Net Sales | $440.5 million | $872.3 million |
| Operating Income | $48.0 million | $88.5 million |
| Net Income (Attributable to AptarGroup) | $28.5 million | $55.1 million |
| Diluted EPS | $0.41 | $0.79 |
| Operating Margin | 10.9% | 10.2% |
| Cash and Equivalents | $249.1 million (Balance Sheet) | $249.1 million (Balance Sheet) |
| Net Debt to Net Capital Ratio | 4% | 4% |
| Operating Cash Flow (6 months) | N/A | $139.1 million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 20% for the quarter and 19% for the six months compared to the prior year. Approximately 9% of the decline was attributed to the strengthening U.S. dollar, while the remaining 11% was due to soft economic conditions and lower product/tooling sales.
- Profitability: Operating income fell 28% for the quarter and 28% for the six months. Net income decreased 37% for the quarter and 33% for the six months.
- Cost Structure: Cost of sales as a percentage of net sales improved (decreased) to 65.6% in Q2 2009 from 67.6% in Q2 2008, driven by cost savings efforts, declining raw material costs, and a favorable product mix (higher Pharma sales). However, SG&A expenses as a percentage of sales increased due to lower sales volumes.
- Unusual Items: The company incurred $3.1 million in facilities consolidation and severance expenses in Q2 2009, with no corresponding expense in the prior year. Total estimated costs for the program are approximately $7 million.
- Segment Performance:
- Beauty & Home: Sales down 26%; Segment income down 58% due to under-absorbed fixed costs and volume declines.
- Closures: Sales down 15%; Segment income increased 10% despite severance charges, aided by cost savings and resin cost pass-throughs.
- Pharma: Sales down 12%; Segment income down 12%, primarily due to unfavorable currency translation.
Guidance, Outlook, and Risks
- Outlook: Management expects a "prolonged, gradual journey" out of the economic downturn with low visibility. They anticipate continuing soft economic conditions to negatively affect results.
- Q3 Guidance: Excluding facility consolidation charges, diluted EPS for the third quarter is anticipated to be in the range of $0.44 to $0.49. The company expects approximately $2.6 million in additional consolidation/severance costs in Q3.
- Liquidity: The company maintains a strong balance sheet with a Net Debt to Net Capital ratio of 4%. It has the ability to borrow an additional $1.2 billion before exceeding its 55% debt-to-total-capital covenant.
- Risks: Key risks include significant fluctuations in foreign currency exchange rates (particularly the Euro), availability and cost of raw materials (resin), customer spending levels, and the successful implementation of a new worldwide ERP system.
Investor Verification Checklist
- Verify the impact of the strengthening U.S. dollar on future revenue translation, given 57% of sales come from Europe.
- Monitor the execution and cost savings realization of the $7 million facilities consolidation and severance program.
- Assess the sustainability of the improved cost of sales percentage amidst potential raw material price volatility.
- Review the "Beauty & Home" segment's ability to recover volume, as it faced the steepest decline (26% sales drop) and profitability compression.
- Confirm the timeline and integration success of the new worldwide ERP system mentioned in risk factors.